Journal of International Oncology››2017,Vol. 44››Issue (3): 190-192.doi:10.3760/cma.j.issn.1673422X.2017.03.008作
Previous ArticlesNext Articles
Li Jiarun, Ge Qiaofeng, Guo Geng, Wang
Online:
2017-03-08Published:
2017-02-28Contact:
Guo Geng E-mail:guogeng973@163.comSupported by:
National
Natural Science Foundation of China (81201991); China Postdoctoral Science
Foundation (2015M571068, 2016T90115); Project Supported by Beijing
Postdoctoral Research Foundation (2015ZZ56, 2016ZZ43); Natural Science
Foundation of Shanxi Province of China (201601D011127); Program for the
Outstanding Innovative Teams of Higher Learning Institutions of Shanxi
Province (20138); Scientific Research Subject of Shanxi Provincial Health
Department (201301066)
Li Jiarun, Ge Qiaofeng, Guo Geng, Wang . Effect and mechanism of Musashi2 and related signal pathways in genesis and progression of malignant tumorLi Jiarun, Ge Qiaofeng, Guo Geng, Wang Xiaogang.[J]. Journal of International Oncology, 2017, 44(3): 190-192.
[1] Sutherland JM, Sobinoff AP, Gunter KM, et al. Knockout of RNA binding protein Msi2 impairs follicle development in the mouse ovary: characterization of Msi1 and Msi2 during folliculogenesis[J]. Biomolecules, 2015, 5(3): 1228-1244. DOI: 10.3390/biom5.31228. [2] Sutherland JM, Fraser BA, Sobinoff AP, et al. Developmental expression of musashi1 and musashi2 RNAbinding proteins during spermatogenesis: analysis of the deleterious effects of dysregulated expression[J]. Biol Reprod, 2014, 90(5): 92. DOI: 10.1095/biolreprod.113.115261. [3] Taggart J, Ho TC, Amin E, et al. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells[J]. Nat Commun, 2016, 7: 10739. DOI: 10.1038/ncomms10739. [4] Han YX, Ye AF, Zhang Y, et al. Musashi2 silencing exerts potent activity against acute myeloid leukemia and enhances chemosensitivity to daunorubicin[J]. PLoS One, 2015, 10(8): e0136484. DOI: 10.1371/journal.pone.0136484. [5] Kaeda J, Ringel F, Oberender C, et al. Upregulated MSI2 is associated with more aggressive chronic myeloid leukemia[J]. Leuk Lymphoma, 2015, 56(7): 21052113. DOI: 10.3109/10428194.2014.981175. [6] de AndrésAguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis[J] . Curr Opin Hematol, 2012, 19(4): 268-272. DOI: 10.1097/MOH.0b013e328353c778. [7] Park SM, Deering RP, Lu YH, et al. Musashi2 controls cell fate, lineage bias, and TGFbeta signaling in HSCs[J]. J Exp Med, 2014, 211 (1): 71-87. DOI: 10.1084/jem.20130736. [8] Zhang HJ, Tan S, Wang J, et al. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway[J]. Exp Cell Res, 2014, 320(1): 119-127. DOI: 10.1016/j.yexcr.2013.09.009. [9] Park SM, Genen M, Vu L, et al. Musashi2 sustains the mixedlineage leukemiadriven stem cell regulatory program[J]. J Clin Invest, 2015, 125(3): 1286-1298. DOI: 10.1172/JCI78440. [10] Thol F, Winschel C, Sonntag AK, et al. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia[J]. Ann Hematol, 2013, 92(3): 315-323. DOI: 10.1007/s00277012 16375. [11] Di Giacomo D, Pierini V, Barba G, et al. Blast crisis Ph+ chronic myeloid leukemia with NUP98/HOXA13 upregulating MSI2[J]. Mol Cytogenet, 2014, 7: 42. DOI: 10.1186/17558166742. [12] GarcíaAlegría E, Carmen LafitaNavarro M, Aguado R, et al. NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells[J]. Cancer Lett, 2016, 375(1): 92-99. DOI: 10.1016/j.canlet.2016.02.037. [13] Wang MH, Qin SY, Zhang SG, et al. Musashi2 promotes hepatitis B virus related hepatocellular carcinoma progression via the Wnt/betacatenin pathway[J]. Am J Cancer Res, 2015, 5(3): 1089-1100. [14] He L, Zhou XK, Qu C, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelialmesenchymal transition[J]. J Cell Mol Med, 2014, 18(1): 49-58. DOI: 10.1111/jcmm.12158. [15] Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNAbinding protein[J]. Nat Commun, 2015, 6: 6517. DOI: 10.1038/ncomms7517. [16] Sutherland JM, McLaughlin EA, Hime GR, et al. The musashi family of RNA binding proteins: master regulators of multiple stem cell populations[J]. Adv Exp Med Biol, 2013, 786: 233-245. DOI: 10.1007/978 9400766211_13. [17] Cox JL, Wilder PJ, Gilmore JM, et al. The SOX2interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells[J]. PLoS One, 2013, 8(5): e62857. DOI: 10.1371/journal.pone.0062857. [18] Shi K, Bing ZT, Cao GQ, et al. Identify the signature genes for diagnose of uveal melanoma by weight gene coexpression network analysis[ J]. Int J Ophthalmol, 2015, 8(2): 269-274. DOI: 10.3980/j.issn.22223959.2015.02.10. [19] EmadiBaygi M, Nikpour P, MohammadHashem F, et al. MSI2 expression is decreased in grade Ⅱ of gastric carcinoma[J]. Pathol Res Pract, 2013, 209(11): 689-691. DOI: 10.1016/j.prp.2013.07.008. [20] Wuebben EL, Mallanna SK, Cox JL, et al. Musashi2 is required for the selfrenewal and pluripotency of embryonic stem cells[J]. PLoS One, 2012, 7(4): e34827. DOI: 10.1371/journal.pone.0034827. [21] Bennett CG, Riemondy K, Chapnick DA, et al. Genomewide analysis of Musashi2 targets reveals novel functions in governing epithelial cell migration[J]. Nucleic Acids Res, 2016, 44(8): 3788-3800. DOI: 10.1093/nar/gkw207. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||